Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26293439 | 0.94 | PIK3CD (0.34) | DOT1LPOLRMTCYP3A4CYP2C9BTN3A1 | |
| SCHEMBL23819212 | 0.92 | POLRMT (0.39) | DOT1LPOLRMTJAK2JAK1CYP3A4 | |
| SCHEMBL23818779 | 0.88 | POLRMT (0.32) | POLRMTJAK2JAK1CYP3A4CYP2C9 | |
| SCHEMBL26275856 | 0.88 | POLRMT (0.38) | DOT1LPOLRMTJAK2JAK1CYP3A4 | |
| SCHEMBL23818904 | 0.88 | POLRMT (0.38) | DOT1LPOLRMTJAK2JAK1CYP3A4 | |
| SCHEMBL23819124 | 0.88 | JAK2 (0.33) | POLRMTJAK2JAK1AXLMERTK | |
| SCHEMBL26331248 | 0.88 | JAK2 (0.33) | POLRMTJAK2JAK1AXLMERTK | |
| SCHEMBL23803231 | 0.88 | JAK2 (0.33) | POLRMTJAK2JAK1AXLMERTK | |
| SCHEMBL23819153 | 0.88 | JAK2 (0.33) | POLRMTJAK2JAK1AXLMERTK | |
| SCHEMBL26295313 | 0.87 | POLRMT (0.33) | DOT1LPOLRMTCYP3A4CYP2C9BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | DOT1L 3143/4885POLRMT 535/4885JAK2 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.